Lancashire and South Cumbria
Formulary
Formulary
8 Malignant disease and immunosuppression
The majority of systemic anti-cancer therapies are not listed in this formulary as they are included in either the Lancashire and South Cumbria Cancer Alliance SACT protocols or the Cancer Drugs Fund list, produced by NHSE.NHS England commissions some high cost noncancer drugs. A list of high cost drugs commissioned by NHS England can be found here |
08-01-05 Hydroxycarbamide
| Hydroxycarbamide 500mg capsules |
|
Formulary
|
 for Morecambe Bay only.Used for the management of haematological myeloproliferative disorders
including:
• Essential thrombocythaemia
• Chronic myeloid leukaemia
• Primary proliferative polycythaemia (polycythaemia vera)
• Myelofibrosis
• Unclassified myeloproliferative disorders
Shared care only for use in Morecambe Bay region, in all other regions the drug remains Red RAG |
 Hydroxycarbamide (Hydroxyurea) for Haematological Conditions – Shared Care Guideline |
|
Links
Bevacizumab and sunitinib: risk of osteonecrosis of the jaw- Biosimilars policy statement
- Drug Safety Update May 2016: BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation
- Healthier LSC - Immune-Related Adverse Event: Diarrhoea/Colitis
- Healthier LSC - Immune-Related Adverse Event: Diarrhoea/Colitis
- Hydroxycarbamide (Hydroxyurea) for Haematological Conditions – Shared Care Guideline
- LSC Breast Chemotherapy Protocols
- MHRA - risk of cracked or broken vials - July 2014
- MHRA advice: Risk of osteonecrosis of the jaw ( 2011)
- MHRA Drug safety Update April 2017: Ponatinib (Iclusig): risk of vascular occlusive events - updated advice on possible dose reduction
- MHRA Drug Safety Update Aug 2019: Carfilzomib (Kyprolis): reminder of risk of potentially fatal cardiac events
- MHRA Drug Safety Update Aug 2019: Daratumumab (Darzalex): risk of reactivation of hepatitis B virus
- MHRA Drug Safety Update December 2021: Venetoclax (Venclyxto): updated recommendations on tumour lysis syndrome (TLS)
- MHRA Drug Safety Update Jan 2019: Ipilimumab (Yervoy): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation
- MHRA drug Safety Update Jan 2022: Paclitaxel formulations (conventional and nab-paclitaxel): caution required due to potential for medication error
- MHRA Drug Safety Update Jan 2022: Paclitaxel formulations (conventional and nab-paclitaxel): caution required due to potential for medication error
- MHRA Drug Safety Update July 2011: Dexrazoxane (Cardioxane): restriction of use
- MHRA Drug Safety Update July 2017: Nivolumab (Opdivo), pembrolizumab (Keytruda): reports of organ transplant rejection
- MHRA Drug Safety Update July 2020: Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
- MHRA Drug Safety Update July 2020: Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
- MHRA Drug Safety Update July 2020: Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
- MHRA Drug Safety Update July 2020: Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
- MHRA Drug Safety Update July 2020: Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
- MHRA Drug Safety Update July 2020: Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
- MHRA Drug Safety Update July 2020: Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
- MHRA Drug Safety Update July 2020: Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
- MHRA Drug Safety Update July 2020: Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
- MHRA Drug Safety Update July 2020: Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
- MHRA Drug Safety Update July 2020: Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
- MHRA Drug Safety Update July 2020: Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
- MHRA Drug Safety Update July 2020: Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
- MHRA Drug Safety Update July 2020: Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
- MHRA Drug Safety Update July 2020: Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
- MHRA Drug Safety Update July 2020: Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
- MHRA Drug Safety Update June 2019: Lartruvo (olaratumab): withdrawal of the EU marketing authorisation due to lack of efficacy
- MHRA drug Safety Update June 2021: Atezolizumab (Tecentriq) and other immune-stimulatory anti-cancer drugs: risk of severe cutaneous adverse reactions (SCARs)
- MHRA Drug Safety Update June 2021: CDK4/6 inhibitors (abemaciclib, palbociclib, ribociclib): reports of interstitial lung disease and pneumonitis, including severe cases
- MHRA Drug Safety Update May 2012: Epidermal growth factor receptor (EGFR) inhibitors: serious cases of keratitis and ulcerative keratitis
- MHRA Drug Safety Update May 2016: BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation
- MHRA Drug Safety Update May 2016: BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation
- MHRA Drug Safety Update May 2016: BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation
- MHRA Drug Safety Update May 2016: BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation
- MHRA Drug Safety Update May 2016: Idelalisib (Zydelig): interim measures following signal of serious infection and deaths related to infection found in clinical trials
- MHRA Drug Safety Update Nov 2015: Crizotinib (Xalkori): risk of cardiac failure
- MHRA Drug Safety Update Nov 2019: Carfilzomib (Kyprolis): risk of reactivation of hepatitis B virus
- MHRA Drug Safety Update Oct 2018: Ponatinib (Iclusig): reports of posterior reversible encephalopathy syndrome
- MHRA Drug Safety Update Sept 2014: Erlotinib: new safety information
- MHRA Drug Safety Update Sept 2016: Idelalisib (Zydelig): updated indications and advice on minimising the risk of infection
- MHRA Drug SAfety Update: Epidermal growth factor receptor (EGFR) inhibitors: serious cases of keratitis and ulcerative keratitis
- MHRA Drug Safety Update: Ibrutinib (Imbruvica): reports of ventricular tachyarrhythmia; risk of hepatitis B reactivation and of opportunistic infections
- MHRA Drug Safety Update: Panitumumab (Vectibix): risk of necrotising fasciitis
- MHRA Drug Safety Update: Panitumumab (Vectibix): serious hypersensitivity reactions
- MHRA DSU March 2019: Onivyde (irinotecan, liposomal formulations): reports of serious and fatal thromboembolic events
- MHRA: Bevacizumab warning about necrotising fasciitis
- MHRA: importance of establishing wild type RAS (KRAS and NRAS) status before treatment of metastatic colorectal cancer
- MHRA: risk of hepatic injury, including fatal hepatic failure—updated warnings and monitoring guidance
- MHRA: risk of vascular occlusive events with ponatinib
- NHSE: National Cancer Drugs Fund list
- NICE Evidence summary: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
- NICE HST20: Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over
- NICE HST33: Leniolisib for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and over
- NICE NG101: Early and locally advanced breast cancer: diagnosis and management
- NICE NG12: Suspected cancer: recognition and referral
- NICE NG122 : Lung cancer: diagnosis and management
- NICE NG224: Melanoma: assessment and management
- NICE NG47: Haematological cancers: improving outcomes
- NICE NG52: Non-Hodgkin’s lymphoma: diagnosis and management
- NICE NG99: Brain tumours (primary) and brain metastases in adults
- NICE Patient access schemes
- NICE TA 241:CML where treatment with imatinib has failed
- NICE TA 347: Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer
- NICE TA 545: Gemtuzumab ozogamicin for untreated acute myeloid leukaemia
- NICE TA 883: Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma
- NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
- NICE TA101: Prostate cancer (hormone-refractory) - docetaxel
- NICE TA1030: Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer
- NICE TA1034: Anhydrous sodium thiosulfate for preventing hearing loss caused by cisplatin chemotherapy in people 1 month to 17 years with localised solid tumours
- NICE TA1043: Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection
- NICE TA1055: Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy
- NICE TA107: Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer
- NICE TA1079: Fruquintinib for previously treated metastatic colorectal cancer
- NICE TA108: Breast cancer (early) - paclitaxel
- NICE TA109: Breast cancer (early) - docetaxel
- NICE TA118: Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer
- NICE TA118:Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer
- NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
- NICE TA145: Head and neck cancer - cetuximab
- NICE TA162: Lung cancer (non-small-cell) 2nd line- erlotinib
- NICE TA169: Renal cell carcinoma - sunitinib
- NICE TA172: Cetuximab for the treatment of recurrent and/or metastatic squamous cell cancer of the head and neck
- NICE TA176: Colorectal cancer (first line) - cetuximab
- NICE TA178: Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma
- NICE TA178: Renal cell carcinoma
- NICE TA178: temsirolimus for first-line treatment of advanced and/or metastatic renal cell carcinoma
- NICE TA179: Gastrointestinal stromal tumours - sunitinib
- NICE TA183: Cervical cancer (recurrent) - topotecan
- NICE TA184: Lung cancer (small-cell) - topotecan
- NICE TA185: Trabectedin for the treatment of advanced soft tissue sarcoma
- NICE TA189: Hepatocellular carcinoma (advanced and metastatic) - sorafenib (first line)
- NICE TA192: Lung cancer (non-small-cell, first line) - gefitinib
- NICE TA207: Mantle cell lymphoma (relapsed) - temsirolimus (terminated appraisal)
- NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab
- NICE TA209: Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours
- NICE TA214: Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer
- NICE TA214: Breast Cancer with taxane
- NICE TA215: Renal cell carcinoma (first line metastatic) - pazopanib
- NICE TA227: Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer
- NICE TA227: Lung cancer (non-small-cell) maintenance - erlotinib
- NICE TA23: Brain cancer - temozolomide
- NICE TA241: Dasatinib, nilotinib and high dose imatinib for CML
- NICE TA242: Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and pan
- NICE TA251: Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia
- NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
- NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
- NICE TA257: Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2
- NICE TA258: Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer
- NICE TA258: Lung cancer (non-small-cell) 1st line- erlotinib
- NICE TA263: Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer
- NICE TA263: Breast cancer with capecitabine
- NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
- NICE TA269: Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma
- NICE TA284 :Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
- NICE TA284: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
- NICE TA285: Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer
- NICE TA285: Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab
- NICE TA295: Breast cancer - everolimus (with an aromatase inhibitor)
- NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy
- NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer
- NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
- NICE TA321:Dabrafenib for unresectable or metastatic BRAF V600 +ve melanoma
- NICE TA326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours
- NICE TA333: Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment
- NICE TA334: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262)
- NICE TA34: Breast cancer - trastuzumab
- NICE TA359 Idelalisib for treating chronic lymphocytic leukaemia
- NICE TA370: Bortezomib for previously untreated mantle cell lymphoma
- NICE TA371: Trastuzumab emtansine for treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane
- NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
- NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
- NICE TA378: Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy
- NICE TA380 Panobinostat for treating multiple myeloma after at least 2 previous treatments
- NICE TA381 Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy
- NICE TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma
- NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
- NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
- NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
- NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
- NICE TA401: Bosutinib for previously treated chronic myeloid leukaemia
- NICE TA403: Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer
- NICE TA405: Trifluridine–tipiracil for previously treated metastatic colorectal cancer
- NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
- NICE TA408: Pegaspargase for treating acute lymphoblastic leukaemia
- NICE TA411: Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer
- NICE TA414: Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma
- NICE TA416: Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer
- NICE TA417: Nivolumab for previously treated advanced renal cell carcinoma
- NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
- NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
- NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens
- NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
- NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
- NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
- NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
- NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
- NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
- NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
- NICE TA429: Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
- NICE TA432: Everolimus for advanced renal cell carcinoma after previous treatment
- NICE TA434:Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
- NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
- NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
- NICE TA440: Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine
- NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
- NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
- NICE TA451: Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia
- NICE TA457: Carfilzomib for previously treated multiple myeloma
- NICE TA458: Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane
- NICE TA462: Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma
- NICE TA463: Cabozantinib for previously treated advanced renal cell carcinoma
- NICE TA465: Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma
- NICE TA473: Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck
- NICE TA474: Sorafenib for treating advanced hepatocellular carcinoma
- NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer
- NICE TA478: Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma
- NICE TA483: Nivolumab for previously treated squamous non-small-cell lung cancer
- NICE TA484: Nivolumab for previously treated non-squamous non-small-cell lung cancer
- NICE TA487: Venetoclax for treating chronic lymphocytic leukaemia
- NICE TA488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
- NICE TA489: Vismodegib for treating basal cell carcinoma
- NICE TA490: Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy
- NICE TA491: Ibrutinib for treating Waldenstrom’s macroglobulinaemia
- NICE TA492: Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
- NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer
- NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma
- NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
- NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
- NICE TA510: Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
- NICE TA512: Tivozanib for treating advanced renal cell carcinoma
- NICE TA514: Regorafenib for previously treated advanced hepatocellular carcinoma
- NICE TA515: Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen
- NICE TA516: Cabozantinib for treating medullary thyroid cancer
- NICE TA516: Cabozantinib for treating medullary thyroid cancer
- NICE TA517: Avelumab for treating metastatic Merkel cell carcinoma
- NICE TA520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy
- NICE TA523: Midostaurin for untreated acute myeloid leukaemia
- NICE TA524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
- NICE TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
- NICE TA526: Arsenic trioxide for treating acute promyelocytic leukaemia
- NICE TA529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer
- NICE TA530: Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy
- NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
- NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
- NICE TA536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer
- NICE TA541: Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia
- NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma
- NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
- NICE TA55: Guidance on the use of paclitaxel in the treatment of ovarian cancer
- NICE TA550: Vandetanib for treating medullary thyroid cancer
- NICE TA551: Lenvatinib for untreated advanced hepatocellular carcinoma
- NICE TA552: Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia
- NICE TA554: Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years
- NICE TA555: Regorafenib for previously treated advanced hepatocellular carcinoma
- NICE TA558: Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease
- NICE TA561; Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia
- NICE TA562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma
- NICE TA562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma
- NICE TA567: Bosutinib for untreated chronic myeloid leukaemia (terminated appraisal)
- NICE TA569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer
- NICE TA569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer
- NICE TA571: Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib
- NICE TA573: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
- NICE TA577: Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma
- NICE TA579: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
- NICE TA581: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma
- NICE TA584: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer
- NICE TA594: Brentuximab vedotin for untreated advanced Hodgkin lymphoma (terminated appraisal)
- NICE TA595: Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer
- NICE TA598: Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy
- NICE TA604: Idelalisib for treating refractory follicular lymphoma
- NICE TA608:Ibrutinib with rituximab for treating Waldenstrom’s macroglobulinaemia (terminated appraisal)
- NICE TA609: Ramucirumab for treating unresectable hepatocellular carcinoma after sorafenib (terminated appraisal)
- NICE TA611: Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer
- NICE TA612: Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab
- NICE TA618: Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer (terminated appraisal)
- NICE TA621: Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer
- NICE TA628: Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer
- NICE TA630: Larotrectinib for treating NTRK fusion-positive solid tumours
- NICE TA632: Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer
- NICE TA634: Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma (terminated appraisal)
- NICE TA635: Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal)
- NICE TA638: Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer
- NICE TA639: Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer
- NICE TA641: Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma
- NICE TA642: Gilteritinib for treating relapsed or refractory acute myeloid leukaemia
- NICE TA643: Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer
- NICE TA644: Entrectinib for treating NTRK fusion-positive solid tumours
- NICE TA645: Avelumab with axitinib for untreated advanced renal cell carcinoma
- NICE TA646: Glasdegib with chemotherapy for untreated acute myeloid leukaemia (terminated appraisal)
- NICE TA649: Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma
- NICE TA652: Alpelisib with fulvestrant for treating hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer (terminated appraisal)
- NICE TA653: Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
- NICE TA653: Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer
- NICE TA654: Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer
- NICE TA655: Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy
- NICE TA657: Carfilzomib for previously treated multiple myeloma
- NICE TA658: Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma
- NICE TA663: Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia
- NICE TA663: Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia
- NICE TA666: Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma
- NICE TA666: Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma
- NICE TA666: Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma
- NICE TA669: Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more therapies
- NICE TA670: Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor
- NICE TA684: Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease
- NICE TA688 Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer
- NICE TA689: Acalabrutinib for treating chronic lymphocytic leukaemia
- NICE TA691: Avelumab for untreated metastatic Merkel cell carcinoma
- NICE TA693: Olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer
- NICE TA695: Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma
- NICE TA700: Selinexor with low-dose dexamethasone for treating refractory multiple myeloma (terminated appraisal)
- NICE TA702:Ibrutinib with obinutuzumab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (terminated appraisal)
- NICE TA703: Ibrutinib with rituximab for untreated chronic lymphocytic leukaemia (terminated appraisal)
- NICE TA704: Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies
- NICE TA705: Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer
- NICE TA707: Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer
- NICE TA713: Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy
- NICE TA714: Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal)
- NICE TA716: Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency
- NICE TA717: Duvelisib for treating relapsed follicular lymphoma after 2 or more systemic therapies (terminated appraisal)
- NICE TA722: Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement
- NICE TA725: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
- NICE TA726: Daratumumab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)
- NICE TA727: Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)
- NICE TA728: Midostaurin for treating advanced systemic mastocytosis
- NICE TA730:Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours (terminated appraisal)
- NICE TA736: Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy
- NICE TA742: Selpercatinib for treating advanced thyroid cancer with RET alterations
- NICE TA746: Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer
- NICE TA750: Olaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy (terminated appraisal)
- NICE TA754: Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome
- NICE TA756:Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis
- NICE TA760: Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer
- NICE TA761: Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection
- NICE TA762: Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (terminated appraisal)
- NICE TA763: Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable
- NICE TA765: Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable
- NICE TA771: Daratumumab with bortezomib, melphalan and prednisone for untreated multiple myeloma (terminated appraisal)
- NICE TA779: Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency
- NICE TA780: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma
- NICE TA781: Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer
- NICE TA783: Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
- NICE TA785: Nivolumab with cabozantinib for untreated advanced renal cell carcinoma (terminated appraisal)
- NICE TA786: Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies
- NICE TA787: Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable
- NICE TA788:Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy
- NICE TA789: Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations
- NICE TA796: Venetoclax for treating chronic lymphocytic leukaemia
- NICE TA797 Enfortumab vedotin for previously treated locally advanced or metastatic urothelial cancer (terminated appraisal)
- NICE TA810: Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence
- NICE TA811: Duvelisib for treating relapsed or refractory chronic lymphocytic leukaemia after 2 or more treatments (terminated appraisal)
- NICE TA812: Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer
- NICE TA813: Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors
- NICE TA816: Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer
- NICE TA817: Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence
- NICE TA818: Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma
- NICE TA819: Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies
- NICE TA823: Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer
- NICE TA831: Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer
- NICE TA833: Zanubrutinib for treating Waldenstrom’s macroglobulinaemia
- NICE TA839: Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids (terminated appraisal)
- NICE TA840: Ruxolitinib for treating chronic graft versus host disease refractory to corticosteroids (terminated appraisal)
- NICE TA841: with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)
- NICE TA842: Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)
- NICE TA849 Cabozantinib for previously treated advanced hepatocellular carcinoma
- NICE TA849 Cabozantinib for previously treated advanced hepatocellular carcinoma
- NICE TA849 Cabozantinib for previously treated advanced hepatocellular carcinoma
- NICE TA850: Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy
- NICE TA852 Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatments
- NICE TA855: Mobocertinib for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy
- NICE TA857: Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma
- NICE TA858: Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma
- NICE TA86: Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours
- NICE TA862 Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments
- NICE TA865 Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma
- NICE TA866 Regorafenib for previously treated metastatic colorectal cancer
- NICE TA870 Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
- NICE TA872 Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies (replaces TA559)
- NICE TA874 Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma
- NICE TA876 Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer
- NICE TA879: Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal)
- NICE TA881: Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments
- NICE TA886: Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy
- NICE TA887: Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer
- NICE TA891: Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia
- NICE TA893:Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over
- NICE TA894: Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma
- NICE TA895: Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy
- NICE TA897: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
- NICE TA898:Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer
- NICE TA908:Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy
- NICE TA908:Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy
- NICE TA911:Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer
- NICE TA917: daratumumab with lenalidomide and dexamethasone for untreatedmultiple myeloma when a stem-cell transplant is unsuitable
- NICE TA921: Ruxolitinib for treating Polycythaemia (replaces TA356 terminated appraisal)
- NICE TA927:Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments
- NICE TA928:Cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine
- NICE TA931:Zanubrutinib for treating chronic lymphocytic leukaemia
- NICE TA933:Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (terminated appraisal)
- NICE TA954: Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments
- NICE TA957: Momelotinib for treating myelofibrosis-related splenomegaly or symptoms
- NICE TA959: Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis
- NICE TA959: Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis
- NICE TAG129: Multiple myeloma - bortezomib
- NICE TAG228: 1st line treatment of multiple myeloma
- NICE TAG311: Bortezomib for induction therapy in multiple myeloma
- NICETA909:Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer
- Ovarian cancer (advanced): bevacizumab 7.5 mg/kg in combination with paclitaxel and carboplatin for first-line treatment
- Patient Alert Card
Shared Care Guideline - Hydroxycarbamide- Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
- TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
- TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
- TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
- TA879Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal)
- VOTRIENT®▼ (pazopanib) – Important change to frequency of serum liver test